These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2734984)

  • 21. Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogens.
    Levell MJ; Siddall JK; Rowe E; Glashan RW; Robinson MR; Pidcock NB
    Prostate; 1987; 11(1):17-21. PubMed ID: 3658825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of 7alpha-(fluoromethyl)dihydrotestosterone and 7alpha-(fluoromethyl)nortestosterone, structurally paired androgens designed to probe the role of sex hormone binding globulin in imaging androgen receptors in prostate tumors by positron emission tomography.
    Parent EE; Carlson KE; Katzenellenbogen JA
    J Org Chem; 2007 Jul; 72(15):5546-54. PubMed ID: 17585812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys.
    Kim MR; Gupta MK; Travers SH; Rogers DG; Van Lente F; Faiman C
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):203-10. PubMed ID: 10396363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate.
    Krieg M; Bartsch W; Janssen W; Voigt KD
    J Steroid Biochem; 1979 Jul; 11(1B):615-24. PubMed ID: 90754
    [No Abstract]   [Full Text] [Related]  

  • 25. Synergistic effect of testosterone and of a luteinizing hormone-releasing hormone agonist on androgen receptor content in the ventral prostate of castrated rats.
    Fiorelli G; Zoppi S; Kohen F; Motta M
    Steroids; 1989; 53(1-2):195-217. PubMed ID: 2505407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
    de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
    Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum sex hormone binding globulin and testosterone binding after estradiol administration, castration, and their combination in men with prostatic carcinoma.
    Leinonen P; Hammond GL; Lukkarinen O; Vihko R
    Invest Urol; 1979 Jul; 17(1):24-7. PubMed ID: 571863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basis for hormonal management of advanced prostate cancer.
    Geller J
    Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic androgen receptor and plasma testosterone levels in streptozotocin-induced diabetic rats.
    Ho SM
    J Steroid Biochem Mol Biol; 1991 Jan; 38(1):67-72. PubMed ID: 1825471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.
    Nabi G; Seth A; Dinda AK; Gupta NP
    J Clin Pathol; 2004 Feb; 57(2):146-50. PubMed ID: 14747438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for the association between blood prolactin and androgen receptors in BPH.
    Odoma S; Chisholm GD; Nicol K; Habib FK
    J Urol; 1985 Apr; 133(4):717-20. PubMed ID: 2580105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer.
    Ribeiro M; Ruff P; Falkson G
    Am J Clin Oncol; 1997 Dec; 20(6):605-8. PubMed ID: 9391550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mediation by an androgen receptor of the stimulatory effect of testosterone on the growth of a fibrosarcoma in the rat.
    Harraga A; Astre C; Possompes B; Saint Aubert B; Sultan C; Joyeux H
    Anticancer Res; 1995; 15(1):77-82. PubMed ID: 7733645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
    Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content?
    Mobbs BG; Johnson IE; Connolly JG; Thompson J
    J Steroid Biochem; 1983 Sep; 19(3):1279-90. PubMed ID: 6604842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sex hormone-binding globulin (SHBG) on androgen bioactivity in vitro.
    Laurent MR; Helsen C; Antonio L; Schollaert D; Joniau S; Vos MJ; Decallonne B; Hammond GL; Vanderschueren D; Claessens F
    Mol Cell Endocrinol; 2016 Dec; 437():280-291. PubMed ID: 27576188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer.
    Ishikawa S; Soloway MS; Van der Zwaag R; Todd B
    J Urol; 1989 May; 141(5):1139-42. PubMed ID: 2651713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.